Phase 3 Recruiting NIH
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in South Carolina: - Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Ralph H Johnson VA Medical Center — Charleston, South Carolina
- Medical University of South Carolina — Charleston, South Carolina
- Prisma Health Cancer Institute - Easley — Easley, South Carolina
- Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
Phase 3 Recruiting Academic/Other
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal a…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in South Carolina: - Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Prisma Health Cancer Institute - Laurens — Clinton, South Carolina
- Prisma Health Richland Hospital — Columbia, South Carolina
- Prisma Health Cancer Institute - Easley — Easley, South Carolina
- Saint Francis Hospital — Greenville, South Carolina
Phase 3 Recruiting Academic/Other
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05976763
Sites in South Carolina: - Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Medical University of South Carolina — Charleston, South Carolina
- Prisma Health Cancer Institute - Easley — Easley, South Carolina
- Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
- Prisma Health Cancer Institute - Faris — Greenville, South Carolina
Phase 3 Recruiting Network
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…
Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
- Prisma Health Richland Hospital — Columbia, South Carolina
- BI-LO Charities Children's Cancer Center — Greenville, South Carolina
Phase 3 Recruiting Industry
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This st…
Sponsor: Genmab
NCT ID: NCT06191744
Sites in South Carolina: - MUSC Hollings Cancer Center /ID# 259604 — Charleston, South Carolina
- Prisma Health /ID# 259602 — Greenville, South Carolina
Phase 3 Recruiting Industry
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06717347
Sites in South Carolina: - Prisma Health - Upstate ( Site 0158) — Greenville, South Carolina
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refracto…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06084936
Sites in South Carolina: - Medical University of S. Carolina — Charleston, South Carolina
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in South Carolina: - Prisma Health Richland Hospital — Columbia, South Carolina
- BI-LO Charities Children's Cancer Center — Greenville, South Carolina
- Prisma Health Cancer Institute - Eastside — Greenville, South Carolina
Phase 1, Phase 2 Recruiting Network
This phase I/II trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed) or does not…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04315324
Sites in South Carolina: - Prisma Health Richland Hospital — Columbia, South Carolina
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in South Carolina: - Prisma Health Richland Hospital — Columbia, South Carolina
- BI-LO Charities Children's Cancer Center — Greenville, South Carolina
Phase 2 Recruiting Network
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that r…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05890352
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Phase 2 Recruiting Industry
Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still ma…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06890884
Sites in South Carolina: - Medical University of South Carolina ( Site 0153) — Charleston, South Carolina
Phase 1, Phase 2 Recruiting Industry
This is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-…
Sponsor: AstraZeneca
NCT ID: NCT07123454
Sites in South Carolina: - Research Site — Myrtle Beach, South Carolina
Phase 1 Recruiting NIH
This phase I trial tests the safety, side effects, best dose and effectiveness of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS) lymphoma. Lenalid…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04609046
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Phase 1 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) a…
Sponsor: Pfizer
NCT ID: NCT03460977
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
- Parkway Surgery Center — Myrtle Beach, South Carolina
Phase 1 Recruiting Industry
Open-label, multicenter, phase 1 study to investigate the safety, tolerability, and PK of AN4005 in patients with advanced tumors. This study is a first-in-human, dose escalation study with the objective to establish the MTD and/or RP2D of…
Sponsor: Adlai Nortye Biopharma Co., Ltd.
NCT ID: NCT04999384
Sites in South Carolina: - Prisma Health Institute for Translational Oncology Research — Greenville, South Carolina
Phase 1 Recruiting Industry
The purpose of this study is to find out whether IV injection of HCB301 is an effective treatment for different types of advanced solid tumors and relapsed and refractory classical Hodgkin lymphomas and what side effects (unwanted effects)…
Sponsor: FBD Biologics Limited
NCT ID: NCT06487624
Sites in South Carolina: - Prisma Health-Upstate — Greenville, South Carolina
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in South Carolina: - AnMed Health Cancer Center — Anderson, South Carolina
- Prisma Health Richland Hospital — Columbia, South Carolina
- McLeod Regional Medical Center — Florence, South Carolina
- Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
- Tidelands Georgetown Memorial Hospital — Georgetown, South Carolina
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in South Carolina: - AnMed Health Cancer Center — Anderson, South Carolina
- Beaufort Memorial Hospital — Beaufort, South Carolina
- Saint Joseph's/Candler - Bluffton Campus — Bluffton, South Carolina
- Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Medical University of South Carolina — Charleston, South Carolina
Recruiting Network
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer …
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT06002828
Sites in South Carolina: - Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Prisma Health Cancer Institute - Easley — Easley, South Carolina
- Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
- Saint Francis Hospital — Greenville, South Carolina
- Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
Recruiting Network
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in South Carolina: - Massive Bio SYNERGY-AI site — Greenville, South Carolina
Recruiting NIH
Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: * To ob…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT00900198
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
NA Recruiting Industry
Multi-center, randomized, controlled, open-label Phase 2 feasibility trial. Subjects on mechanical ventilation (MV) for acute hypoxemic respiratory failure (AHRF) with lung injury (including subjects who meet criteria for acute respiratory…
Sponsor: Lungpacer Medical Inc.
NCT ID: NCT06832306
Sites in South Carolina: - Prisma Health — Columbia, South Carolina